Amisulpride versus fluoxetine in dysthymia: Preliminary results of a double-blind comparative study

European Psychiatry

Volumn 11, Issue SUPPL. 3, 1996, Pages 141s-143s

  Smeraldi, E ^a   Haefele, E ^a   Crespi, G ^a   Casadei, G L ^b   Biondi, F ^b   Vigorelli, E ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Medical Department   (Italy)

Author keywords

amisulpride; benzamide; dysthymia; fluoxetine; treatment

Indexed keywords

AMISULPRIDE; FLUOXETINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSTHYMIA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029936080     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-9338(96)85189-3     Document Type: Article

References (13)

1. Agnoli A, Ravizza L, Trota R. Studio controllato in doppio cieco nelle sindromi distimiche (amisulpride vs amitriptilina). Suppl II XXXVII Congresso SIP Roma 6-11 Febbraio 1989
2. Boyer P, Lecrubier Y, Puech A et al. Treatment of dysthymia with low doses of amisulpride vs amineptine. Clin Neuropharmacol 1992;15(1B):23
3. Carnoy P, Ravard S, Hervé D et al. Behavioural deficits induced by low doses of apomorphine in rats: evidence for motivational and cognitive dysfunctions which discriminate among neuroleptic drugs. Pharmacol Biochem Behav 1986;25:503-9
4. Frances A. Recurrent brief depression, dysthymia and melancholia. Intern Clin Psychopharmacol 1993;7:197-200
5. Lecrubier Y, Puech AJ, Aubin F et al. Comparative double-blind study of two doses of amisulpride (25 and 50 mg) and placebo in the treatment of the negative syndrome of non-psychotic subjects. In: Borenstein P, Boyer P, Braconnier A et al, eds. Amisulpride. Paris: Expansion Scientifique Française, 1989:167-79
6. Lecrubier Y. Pharmacological intervention in dysthymia. Eur Psychiatry 1996;this issue
7. Martres MP, Sokoloff P, Delandre M, Schwarts JC, Protai P, Costentin J. Selection of dopamine antagonists discriminating various behavioral responders and radioligand binding sites. Arch Pharmacol 1984;325(2):102-15
8. Maubrey MC, Jacquot C, Gonidec J et al. Amisulpride: pharmacological and biochemical profiles. In: Borenstein P, Boyer P, Braconnier A et al, eds. Amisulpride. Paris: Expansion Scientifique Française, 1989:3-23
9. Puech AJ, Simon P, Boissier JR. Benzamides and classical neuroleptics. Comparison of their action using 6-apomorphine-induced effects. Eur J Pharmacol 1978;50:291-300
10. Rioux P. Etude comparative DAN 2163: DAN 2163 comprimés 50 mg/100 mg placebo dans le traitement de l'inhibition psychomotrice chez les malades de type psychasténique. Internal Report. 2163 D 483, 1984 (data on file)
11. Scarzella R, Scarzella L, Rovera GG. Amisulpride vs sulpiride, studio clinico in doppio cieco su 68 pazienti affetti da disturbo distimico. Giornale Neuropsicofarm 1988;2:73-8
12. Stakes PE. Fluoxetine: a five-year review. Clin Ther 1993;15:216-43
13. Ungersted U, Herrera-Marschitz M, Sharp T, Stachle L, Tossmann U, Zettrestrom T. Caracterisation pharmacologique de Dogmatil: effets pré et post synaptiques sur les récepteurs dopaminergiques. Sem Hôp Paris 1985;61(19):1283-7